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remains to be defined. Epithelial-to-mesenchymal transition
(EMT) has emerged as a critical step in the conversion of early
stage to aggressive cancer. Employing our previously established
stable human cancer cell lines {prostate (LNCaP), breast (MCF-7)
and fibrosarcoma (HT1080) cells} over expressing MT1-MMP-GFP
(MT1-GFP) as well as GFP expressing control cells (Thromb Hae-
most 93:770–8; 2005), we examined the role of MT1-MMP in pro-
moting EMT. Expression of MT1-MMP in all three cell lines
promoted cell proliferation in 3 dimensional (3D) cultures, but
not in 2D cultures. Enzymatic activity of MT1-MMP is required
for enhanced cell proliferation suggesting that cellular degrada-
tion of surrounding collagen is a prerequisite. GFP-expressing
control LNCaP and MCF-7 cells cultivated in 3D type I collagen
gels gradually formed spherical aggregates, whereas cells
expressing MT1-GFP displayed a scattered growth pattern.
MT1-MMP-induced cell scattering was abrogated by targeted
inhibition of either the catalytic domain (TIMP-2) or the hemo-
pexin domain (recombinant PEX) domain of MT1-MMP, indicat-
ing a specific role for each domain in cell scattering. Abrogation
of MT1-MMP-induced phenotypic changes (fibroblast-like mor-
phology and cell scattering) was reversible upon withdrawal of
inhibitors. MT1-MMP transfected LNCaP and MCF-7 cells also
degraded the cell–cell adherins junction molecule, E-cadherin.
In contrast to epithelial carcinoma (LNCaP, MCF-7), non trans-
fected HT1080 cells, which are mesenchymal in origin, dis-
played a scattered growth pattern in 3D collagen gels.
Transfection of HT1080 cells with MT1-MMP or treatment with
high dose TIMP-2, did not alter the scattered growth pattern
of HT1080 cells. These results are consistent with experiments
demonstrating that mesenchymal-amoeboid cell invasion is
independent of MMP activity (Wolf, K., et al. J. Cell Biol. 160:
267–77; 2003). We hypothesize that MT1-MMP degradation of
E-cadherin and collagen induce signal transduction pathways
leading to mesenchymal-associated morphologic changes and
promoting cancer cell migration and proliferation in 3D colla-
gen gels, thus recapitulating EMT. The central role of MT1-
MMP in epithelial cancer progression provides a stimulus for
development of specific inhibitors as treatment of early stage
cancer.
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S14. CROSS-ANALYSIS OF GENE AND miRNA EXPRESSION IN
HEREDO-FAMILIAL BREAST CANCERS
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Five to ten percent of all breast carcinomas originate from a
hereditary predisposition. Some of them have been associated
to mutations in the BRCA1 and BRCA2 susceptibility genes.
However, a large number of hereditary breast cancer cases are
not accounted by mutations in these two genes and are
believed to be due to as yet unidentified breast cancer predispo-
sition genes (BRCAX). Despite intensive effort, their identifica-
tion has been so far unsuccessful, presumably because of
genetic heterogeneity, low penetrance, or recessive/polygenic
mechanisms.
We have performed a comprehensive transcriptional profiling
analysis on a group of tumor specimens from BRCA patients with
the aim to find if the different genetic condition can distinguish
BRCA1, BRCA2 and BRCAX cases and is able to explain the heter-
ogeneity of BRCAX families. Moreover, we have integrated mRNA
and MiRNA analyses on the same cases to identify MiRNA depen-
dent mechanisms involved in hereditary breast cancer. We have
analyzed 50 familial breast cancer cases consisting in 18 samples
from patients characterized by carrying germ-line mutations of
BRCA1 gene, 11 samples with BRCA2 mutations and 20 samples
from BRCAX patients, respectively. As a control, 13 tumors from
patients with no family history of breast cancer were similarly
analyzed.
Since microarray studies showed that the main clusteriza-
tion in terms of gene expression profiles of breast cancers fol-
lows the status ER+ (estrogen receptor positive) and
ER (estrogen receptor negative), we applied a linear model that
adjusted for ER status the sample analysis. After the adjust-
ment, class comparison studies show that only BRCA1 samples
exhibited a significant number of differentially expressed genes
compared to any of the other hereditary or non-hereditary
groups of samples.
Interestingly, BRCAX cases cluster into two distinct sub-
groups, one mixed up to BRCA2 and sporadic cases, the other clo-
ser to BRCA1 samples, and containing only BRCAX cases. The dis-
tinct biological identity of the two sub-groups is further
supported by the fact that the same bipartition occurs when we
used the 6 genes common between our and Hedenfalk et al.’s
(PNAS, 100: 2532–7; 2003) classifier which defines BRCAX sub-
groups. Clinical characteristics of the tumors show that those
belonging to the group containing only BRCAX cases are similar
to BRCA1 tumors. Samples mixed to BRCA2 and sporadic cases
are more heterogeneous, suggesting a possible involvement of
low penetrance genes.
Analysis of the same cases by miRNA expression profile on an
array containing 245 miRNA from human and mouse genome
highlighted that miRNA deregulation is a frequent event in spo-
radic breast cancer and distinguishes it from the heredo-familial
cases. It is also worth noting that MiRNA analysis confirmed the
existence of the two BRCAX sub-groups.
We are now integrating gene expression and miRNA data to
identify the targets of the miRNAs found as differentially
expressed in the groups in analysis.
The work of the authors is supported by a grant of the Italian
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S15. USE OF SPECIALIZED ARRAYS FOR THE DIAGNOSIS OF
PANCREATIC TUMOURS
Thomas M. Gress. Philipps University Marburg, Germany.
DNA array technology holds great promises for the improvement
of diagnostic procedures in many medical fields. We demon-
strate that expression profiling analyses of FNAB samples using
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specialized diagnostic arrays significantly improves the accuracy
of diagnosis of suspect masses in the pancreas. We have con-
structed diagnostic arrays to only contain genes with diagnostic
and/or prognostic potential for the classification of pancreatic
tissues, augmented with control features. Our results demon-
strate that this setup is suitable to produce reliable, reproducible
and informative expression profiles of pancreatic tissues and
biopsy samples. Expression profiling analysis using the special-
ized diagnostic array in conjunction with conventional cytology
allows the distinction between pancreatic ductal adenocarci-
noma (PDAC) and non-malignant diseases of the pancreas with
almost 100% diagnostic accuracy. We are currently in the process
of analyzing additional tumor entities, such as acinar and neu-
roendocrine tumors, using both the diagnostic array as well as
large scale arrays, in order to develop a multiclass classification
system for the comprehensive diagnosis of different malignan-
cies in the pancreas. In addition, we expect further development
of the array in combination with careful analysis of clinical
patient data to result in the recognition of distinct prognostic
gene expression signatures predicting important clinical param-
eters such as stage of disease, response to therapy, or prognosis.
Specialized DNA arrays thus represent valuable new diagnostic
tools which can significantly expand the range of information
gained in routine diagnostic procedures, thus providing a better
basis for decisions on treatment options and setting the stage
for therapeutic regimens custom tailored to the individual
patient.
doi:10.1016/j.ejcsup.2006.04.016
S16. HIERARCHICAL NEURAL NET TECHNOLOGY FOR
MOLECULAR STAGING WITH CLINICAL DATA
R. Katesa,b, H. Allgayerc, N. Harbeckb. aREK Consulting,
Germany; bTechnical University of Munich, Germany; cDepartment of
Experimental Surgery, Universita¨tsklinikum Mannheim, Ruprecht-
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Trained neural networks can be used to construct scoring mod-
els for molecular staging in cancer. They offer considerable flex-
ibility for representing nonlinear interactions, but because of
their flexibility they also tend to require substantial ‘‘training’’
data. It often happens that clinical factors are available in a
large collective, but molecular data is available only for a smaller
subset. A hierarchical neural net training architecture is pre-
sented here. Hierarchical nets are trained in levels, the first level
on a large cohort with limited (usually clinical) factors, the sec-
ond and possibly higher levels on cohort subsets with more
(usually molecular) factors, and so on. The scores produced at
the first level are treated as ‘‘factors’’ for the second level, and
so on. In diseases with distinctly classifiable modes or sites of
recurrence (e.g., bone vs. soft tissue in breast cancer), the ‘‘com-
peting’’ risks can be modelled within the neural network archi-
tecture. To test the hypothesis that a molecular staging factor
might signal the particular relapse mode, one can study signifi-
cant correlations between factors and ‘‘hidden’’ nodes of a
trained neural network. A method is also described for using
trained neural nets to generate hypotheses about potential sub-
groups for molecular staging targets. Applications to breast,
colon, and gastric cancer are reviewed.
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S17. BIOINFORMATICS TOOLS FOR MOLECULAR CANCER
DIAGNOSTICS ON MICROARRAYS
Jo¨rg Hoheisel. Functional Genome Analysis, German Cancer Research
Center, Heidelberg, Germany.
In the Division of Functional Genome Analysis at DKFZ, we are devel-
oping technologies for the identification, description and evalua-
tion of cellular functions and their regulation by producing and
processing biological information on a genomic scale. Many
chemical and biophysical issues are being addressed in an
attempt to understand the underlying procedural aspects,
thereby establishing superior analysis processes.
Concerning human material, systems are being developed
toward early diagnosis, prognosis and evaluation of the success
of disease treatment with an accentuation on cancer. To this
end, comparative studies on epigenetic and splice variations,
transcription factor binding, transcriptional activity and actual
protein expression are under way. Early diagnosis from body flu-
ids is being worked at that is based on the binding of their com-
ponents to peptide and antibody microarrays.
Combining this data with clinical information permits the
definition of patient sub-groups and may provide a robust
means for diagnosis and prognosis and lead to the identification
of relevant molecular activities. We have established processes –
both experimentally and in the area of bioinformatics – to deal
with this challenge. The combination will not only occur in sil-
ico, since the various molecular levels affect each other exten-
sively. Soon, current in silico systems biology will translate
into ever more complex experimental set-ups that permit an
evaluation of a biological issue in a systemic experimentation.
Similar to research in physics, an iterative interaction of theoret-
ical and experimental systems biology will yield important
insights into function, providing the archetypal platform for an
eventual model of a cell.
doi:10.1016/j.ejcsup.2006.04.018
S18. CONVENTIONAL STATISTICAL METHODOLOGY IN LARGE
SCALE PROFILING
Rainer Spang. Max Planck Institute for Molecular Genetics, Berlin,
Germany.
A plethora of computational methods for the diagnosis of can-
cer using gene expression profiling has been suggested. This
might come as a surprise, since diagnosis appears to be a
straightforward classification problem. What can be done with
methods from standard statistics textbooks? Clearly, the prob-
lem is the large number of genes on the arrays. Including them
all in a classification model leads to saturation of the model.
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